CDC FDA Vaccine Panel Conflict Study Reveals Limited Disagreements
- Concerns about potential biases influencing vaccine recommendations are easing, according to a new study published in JAMA.
- The study examined data from the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) and the Food and Drug Administration's (FDA) Vaccines and...
- 13.5% of ACIP panel members declared some form of conflict of interest between 2000 and 2024,compared to 4% of those serving on the FDA vaccine panel.
Declining Conflicts of Interest on Vaccine Advisory Panels
Table of Contents
Published August 19, 2025
The Trend Towards Transparency
Concerns about potential biases influencing vaccine recommendations are easing, according to a new study published in JAMA. The research reveals that declared conflicts of interest among members of key federal vaccine advisory panels have reached “historically low levels” in recent years. This finding arrives as Health and Human Services Secretary Robert F. Kennedy jr. has publicly questioned the impartiality of these groups.
The study examined data from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) and the Food and Drug Administration’s (FDA) Vaccines and Related biological Products Advisory Committee. Between 2000 and 2024, the rate of conflicts among ACIP members plummeted from nearly 43% to just 5% last year. Simultaneously,conflicts on the FDA panel fell from 11% to 0% over the same period.
Understanding the Nature of Conflicts
13.5% of ACIP panel members declared some form of conflict of interest between 2000 and 2024,compared to 4% of those serving on the FDA vaccine panel. The most common type of conflict involved research funding – accounting for 10% of disclosures among ACIP members and nearly 1% on the FDA panel. Other, less frequent conflicts included consulting arrangements, stock or patent ownership, and roles on company data monitoring boards.
| Panel | Conflict Rate (2000) | Conflict Rate (2024) |
|---|---|---|
| ACIP | ~43% | 5% |
| FDA | 11% | 0% |
Why This Matters
Maintaining public trust in vaccine recommendations is paramount. Transparency regarding potential conflicts of interest is a crucial component of that trust. While some level of engagement with the pharmaceutical industry is frequently enough unavoidable for leading researchers in the field, minimizing and disclosing these connections is essential to ensure unbiased decision-making.